Nalmefene for alcohol dependence: new evidence casts doubt over NICE recommendations

5006945413_c9e97ac841_b

Matt Field presents new evidence on the risks and benefits of nalmefene in the treatment of adult alcohol dependence, which casts further doubt over the controversial recommendations made by NICE and the European Medicines Agency.

[read the full story...]

Acamprosate and oral naltrexone may improve consumption related outcomes for people with alcohol use disorders

shutterstock_141815629

A new systematic review suggests that, when used alongside psychosocial interventions, medication can result in better alcohol consumption outcomes for people with drinking problems.

[read the full story...]

Should we be prescribing medication to help people with alcohol use disorders?

shutterstock_128350532

Alcohol Use Disorders (AUDs) are common, chronic conditions which cause substantial harm to the individual and society. They are associated with substantial morbidity (Schuckit, 2009) and responsible for approximately 4% of all deaths annually. The approximate cost of AUDs to the National Health Service is upwards of £3 billion per year. Less than one-third of [read the full story…]

Naltrexone as part of positive behavioural support appeared to have positive impact on self injurious behavour

Health_Meeting-3

Self injurious behaviour in people with learning disabilities can have a major impact on quality of life, in addition to physical harm. Positive behaviour approaches have been showing some degree of success in supporting people with self injurious behaviour, and this case study investigated the possibility of combining pharmacological strategies with positive behaviour support plans. [read the full story…]